These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19817870)

  • 1. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.
    Steckelings UM; Rompe F; Kaschina E; Unger T
    Fundam Clin Pharmacol; 2009 Dec; 23(6):693-703. PubMed ID: 19817870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin angiotensin system (RAS) blockade and diabetic microvascular complications in the eye and kidney.
    Bilous R
    Prim Care Diabetes; 2008 Dec; 2(4):201-2. PubMed ID: 18760685
    [No Abstract]   [Full Text] [Related]  

  • 4. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
    Nagai N; Izumi-Nagai K; Oike Y; Koto T; Satofuka S; Ozawa Y; Yamashiro K; Inoue M; Tsubota K; Umezawa K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4342-50. PubMed ID: 17724226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The renin-angiotensin system and diabetic nephropathy.
    Gurley SB; Coffman TM
    Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving microvascular outcomes in patients with diabetes through management of hypertension.
    McGill JB
    Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A; Teo KK
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of angiotensin II in diabetic nephropathy.
    Kennefick TM; Anderson S
    Semin Nephrol; 1997 Sep; 17(5):441-7. PubMed ID: 9316212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
    Karalliedde J; Viberti G
    J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the renin-angiotensin system and target organ protection.
    Iwanami J; Mogi M; Iwai M; Horiuchi M
    Hypertens Res; 2009 Apr; 32(4):229-37. PubMed ID: 19262496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes].
    Strawn WB
    Drugs; 2002; 62 Spec No 1():31-41. PubMed ID: 12036387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications.
    Cooper ME
    Am J Hypertens; 2004 Nov; 17(11 Pt 2):16S-20S; quiz A2-4. PubMed ID: 15539106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms for the clinical benefits of angiotensin II receptor blockers.
    Schmieder RE
    Am J Hypertens; 2005 May; 18(5 Pt 1):720-30. PubMed ID: 15882557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin receptor blockers: novel role in high-risk patients.
    Javed U; Deedwania PC
    Cardiol Clin; 2008 Nov; 26(4):507-26. PubMed ID: 18929228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension and diabetes: role of the renin-angiotensin system.
    Jandeleit-Dahm K; Cooper ME
    Endocrinol Metab Clin North Am; 2006 Sep; 35(3):469-90, vii. PubMed ID: 16959581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
    Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
    Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.